Trevi Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 5, 2026
TRVI$14.91-2.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Comprehensive Loss
(Amounts in thousands, except share and per share amounts)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating expenses: | ||
| Research and development | $9,941 | $7,811 |
| General and administrative | 4,971 | 3,659 |
| Total operating expenses | 14,912 | 11,470 |
| Loss from operations | (14,912) | (11,470) |
| Other income (expense): | ||
| Interest income, net | 1,696 | 1,125 |
| Other income (expense), net | 4 | (6) |
| Total other income, net | 1,700 | 1,119 |
| Loss before income taxes | (13,212) | (10,351) |
| Income tax benefit | (20) | (11) |
| Net loss | $(13,192) | $(10,340) |
| Basic and diluted net loss per common share outstanding | $(0.09) | $(0.09) |
| Weighted average common shares used in net loss per share attributable to common stockholders, basic and diluted | 145,592,901 | 117,610,750 |
| Net loss | $(13,192) | $(10,340) |
| Other comprehensive (loss) income: | ||
| Net unrealized (losses) gains on available-for-sale marketable securities | (338) | 12 |
| Comprehensive loss | $(13,530) | $(10,328) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.